RU2749950C2 - Применение композиции, состоящей из аминокислот глицина, аргинина, цистеина и ресвератрола, для снижения тяжести диабета и высокого содержания жира в организме, холестерина, мочевой кислоты, глюкозы в крови и ускоренного старения у животных и человека - Google Patents

Применение композиции, состоящей из аминокислот глицина, аргинина, цистеина и ресвератрола, для снижения тяжести диабета и высокого содержания жира в организме, холестерина, мочевой кислоты, глюкозы в крови и ускоренного старения у животных и человека Download PDF

Info

Publication number
RU2749950C2
RU2749950C2 RU2018147077A RU2018147077A RU2749950C2 RU 2749950 C2 RU2749950 C2 RU 2749950C2 RU 2018147077 A RU2018147077 A RU 2018147077A RU 2018147077 A RU2018147077 A RU 2018147077A RU 2749950 C2 RU2749950 C2 RU 2749950C2
Authority
RU
Russia
Prior art keywords
composition
resveratrol
cysteine
arginine
animals
Prior art date
Application number
RU2018147077A
Other languages
English (en)
Russian (ru)
Other versions
RU2018147077A3 (enExample
RU2018147077A (ru
Inventor
ДЕ ЛА ВЕГА Горацио АСТУДИЙО
Original Assignee
ДЕ ЛА ВЕГА Горацио АСТУДИЙО
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ДЕ ЛА ВЕГА Горацио АСТУДИЙО filed Critical ДЕ ЛА ВЕГА Горацио АСТУДИЙО
Priority claimed from PCT/MX2017/000061 external-priority patent/WO2017213486A2/es
Publication of RU2018147077A publication Critical patent/RU2018147077A/ru
Publication of RU2018147077A3 publication Critical patent/RU2018147077A3/ru
Application granted granted Critical
Publication of RU2749950C2 publication Critical patent/RU2749950C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
RU2018147077A 2015-06-08 2017-06-08 Применение композиции, состоящей из аминокислот глицина, аргинина, цистеина и ресвератрола, для снижения тяжести диабета и высокого содержания жира в организме, холестерина, мочевой кислоты, глюкозы в крови и ускоренного старения у животных и человека RU2749950C2 (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562172339P 2015-06-08 2015-06-08
US15/176,422 2016-06-08
US15/176,422 US10285963B2 (en) 2015-06-08 2016-06-08 Combination of metabolic bio-energetic and nutra-epigentic regulators, nutraceutical compounds in conventional and nanotechnologies combination to revert and prevent the chronic damage accelerated cellular senescence produced by diabetes and other degenerative chronic complex diseases
MXMX/A/2017/007448 2017-06-07
MX2017007448A MX365886B (es) 2015-06-08 2017-06-07 Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciones convencionales y nanotecnológicas para revertir y prevenir la senescencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas.
PCT/MX2017/000061 WO2017213486A2 (es) 2016-06-08 2017-06-08 Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciónes convencionales y nanotecnológicas para revertir y prevenir la sesencencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas

Publications (3)

Publication Number Publication Date
RU2018147077A RU2018147077A (ru) 2020-07-10
RU2018147077A3 RU2018147077A3 (enExample) 2020-09-21
RU2749950C2 true RU2749950C2 (ru) 2021-06-21

Family

ID=57450744

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018147077A RU2749950C2 (ru) 2015-06-08 2017-06-08 Применение композиции, состоящей из аминокислот глицина, аргинина, цистеина и ресвератрола, для снижения тяжести диабета и высокого содержания жира в организме, холестерина, мочевой кислоты, глюкозы в крови и ускоренного старения у животных и человека

Country Status (8)

Country Link
US (1) US10285963B2 (enExample)
JP (1) JP2019521184A (enExample)
CN (1) CN109890369B (enExample)
BR (1) BR112018075395A2 (enExample)
CA (1) CA3027048A1 (enExample)
ES (1) ES2988151T3 (enExample)
MX (1) MX365886B (enExample)
RU (1) RU2749950C2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3470060B1 (en) * 2016-06-08 2024-07-31 Astudillo De La Vega, Horacio Composition comprising resveratrol, glycine, arginine and cysteine for use in treating metabolic syndrome

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2163252A1 (en) * 2007-05-17 2010-03-17 Kaneka Corporation Composition containing licorice-derived polyphenol

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006273834A (ja) * 2004-06-28 2006-10-12 Kao Corp Ａｍｐｋ活性化剤
US7709539B2 (en) * 2004-08-11 2010-05-04 Chang Gung University Therapeutic use of resveratrol for hyperglycemia
ITPD20050224A1 (it) * 2005-07-19 2007-01-20 Actimex Srl Composizioni contenenti micronutrienti aventi in particolare attivita' antiossidante e loro impiego
WO2007035612A2 (en) * 2005-09-16 2007-03-29 Ordway Research Institute, Inc. Polyphenol conjugates as rgd-binding compounds and methods of use
JP5594819B2 (ja) * 2009-12-22 2014-09-24 キリンホールディングス株式会社 脂質代謝改善用組成物
JP2012041296A (ja) * 2010-08-19 2012-03-01 Medience Corp 血管内皮機能改善剤、一酸化窒素産生促進剤、及び飲食品
EP3466418A1 (en) * 2011-07-15 2019-04-10 NuSirt Sciences, Inc. Compositions and methods for modulating metabolic pathways

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2163252A1 (en) * 2007-05-17 2010-03-17 Kaneka Corporation Composition containing licorice-derived polyphenol

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
CHEN H. et al. The effect of resveratrol on the recurrent attacks of gouty arthritis // Clin Rheumatol. 2016 May. Vol. 35(5). P. 1189-1195. *
CHEN H. et al. The effect of resveratrol on the recurrent attacks of gouty arthritis // Clin Rheumatol. 2016 May. Vol. 35(5). P. 1189-1195. LIU K. et al. Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials // Am J Clin Nutr. 2014. Vol. 99. P. 1510-1519. MACARULLA M.T. et al. Effects of different doses of resveratrol on body fat and serum parameters in rats fed a hypercaloric diet // J Physiol Biochem. 2009. Vol. 65(4). P. 369-376. MсCARTY M.F. et al. The cardiometabolic benefits of glycine: Is glycine an ‘antidote’ to dietary fructose? // Open Heart. 2014. Vol. 1. e000103. GANNON M.C. et al. The metabolic response to ingested glycine // Am J Clin Nutr. 2002. Vol. 76. P. 1302-1307. PARK T. et al. Dietary taurine or glycine supplementation reduces plasma and liver cholesterol and triglyceride concentrations in rats fed a cholesterol-free diet // Nutrition Research. 1999. Vol. 19(12). P. 1777-1789. TRIPATHI P. et al. Role of *
FU W.J. et al. Dietary L-Arginine Supplementation Reduces Fat Mass in Zucker Diabetic Fatty Rats // J Nutr. 2005. Vol. 135(4). P. 714-721. *
GANNON M.C. et al. The metabolic response to ingested glycine // Am J Clin Nutr. 2002. Vol. 76. P. 1302-1307. *
JAIN S.K. et al. L-cysteine supplementation lowers blood glucose, glycated hemoglobin, CRP, MCP-1, oxidative stress and inhibits NFkB activation in the livers of Zucker diabetic rats // Free Radic Biol Med. 2009. Vol. 46(12). P. 1633-1638. *
LIU K. et al. Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials // Am J Clin Nutr. 2014. Vol. 99. P. 1510-1519. *
LUCOTTI P. et al. Beneficial effects of a long-term oral L-arginine treatment added to a hypocaloric diet and exercise training program in obese, insulin-resistant type 2 diabetic patients // Am J Physiol Endocrinol Metab. 2006. Vol. 291. P. E906-E912. *
MACARULLA M.T. et al. Effects of different doses of resveratrol on body fat and serum parameters in rats fed a hypercaloric diet // J Physiol Biochem. 2009. Vol. 65(4). P. 369-376. *
Mashkovsky M.D. Medicines - 16th ed., Revised, revised. and add. - M .: Novaya Volna, 2012 .-- 1216 p. *
MсCARTY M.F. et al. The cardiometabolic benefits of glycine: Is glycine an ‘antidote’ to dietary fructose? // Open Heart. 2014. Vol. 1. e000103. *
PARK T. et al. Dietary taurine or glycine supplementation reduces plasma and liver cholesterol and triglyceride concentrations in rats fed a cholesterol-free diet // Nutrition Research. 1999. Vol. 19(12). P. 1777-1789. *
SUGIYAMA K. at al. Effects of Methionine, Cystine and Taurine on Plasma Cholesterol Level in Rats Fed a High Cholesterol Diet // Agric. Biol. Chem. 1984. Vol. 48(11). P. 2897-2899. *
TRIPATHI P. et al. Role of L-Arginine on Dyslipidemic Conditions of Acute Myocardial Infarction Patients // Ind J Clin Biochem. 2012. Vol. 27(3). P. 296-299. *
Машковский М.Д. Лекарственные средства - 16-е изд., перераб., испр. и доп. - М.: Новая волна, 2012. - 1216 с. *

Also Published As

Publication number Publication date
RU2018147077A3 (enExample) 2020-09-21
ES2988151T3 (es) 2024-11-19
CN109890369B (zh) 2022-04-29
JP2019521184A (ja) 2019-07-25
BR112018075395A2 (pt) 2019-04-02
US10285963B2 (en) 2019-05-14
CA3027048A1 (en) 2017-12-14
MX365886B (es) 2019-06-19
CN109890369A (zh) 2019-06-14
US20160354331A1 (en) 2016-12-08
RU2018147077A (ru) 2020-07-10
MX2017007448A (es) 2018-09-10

Similar Documents

Publication Publication Date Title
Inchingolo et al. Benefits and implications of resveratrol supplementation on microbiota modulations: a systematic review of the literature
Sheng et al. Grape seed proanthocyanidin extract ameliorates dextran sulfate sodium-induced colitis through intestinal barrier improvement, oxidative stress reduction, and inflammatory cytokines and gut microbiota modulation
Tsuda Recent progress in anti-obesity and anti-diabetes effect of berries
Talagavadi et al. Cyanidin-3-O-β-glucoside and protocatechuic acid activate AMPK/mTOR/S6K pathway and improve glucose homeostasis in mice
CA2917712C (en) Compositions prepared from poultry and methods of their use
Zhou et al. Tetrahydroxystilbene glucoside extends mouse life span via upregulating neural klotho and downregulating neural insulin or insulin-like growth factor 1
Liu et al. Dietary polyphenols as anti-aging agents: targeting the hallmarks of aging
Qu et al. Theaflavin promotes mitochondrial abundance and glucose absorption in myotubes by activating the CaMKK2-AMPK signal axis via calcium-ion influx
Mei et al. Studies on protection of astaxanthin from oxidative damage induced by H2O2 in RAW 264.7 cells based on 1H NMR metabolomics
Li et al. Ellagic acid alters muscle fiber-type composition and promotes mitochondrial biogenesis through the AMPK signaling pathway in healthy pigs
Li et al. Safety assessment of desaminotyrosine: Acute, subchronic oral toxicity, and its effects on intestinal microbiota in rats
JP6510004B2 (ja) イミダゾールジペプチドを含有するエクソソーム調節剤、およびエクソソームを含有する神経細胞活性化剤
RU2749950C2 (ru) Применение композиции, состоящей из аминокислот глицина, аргинина, цистеина и ресвератрола, для снижения тяжести диабета и высокого содержания жира в организме, холестерина, мочевой кислоты, глюкозы в крови и ускоренного старения у животных и человека
KR20190080877A (ko) 유기 셀레늄 화합물 함유 조성물
Niewiadomska et al. Effects of Punica granatum L. peel extract supplementation on body weight, cardiac function, and haematological and biochemical parameters in an animal model of metabolic syndrome
Ghosh et al. Melatonin protects against lead acetate-induced changes in blood corpuscles and lipid profile of male Wistar rats
Shipelin et al. Comprehensive assessment of the effectiveness of l-carnitine and transresveratrol in rats with diet-induced obesity
EP3470060B1 (en) Composition comprising resveratrol, glycine, arginine and cysteine for use in treating metabolic syndrome
Khan et al. Assessment of the role of anthocyanin standardized elderberry (Sambucus nigra) extract as an immune-stimulating nutraceutical of Nile tilapia, Oreochromis niloticus
CN117100740A (zh) 双氢青蒿素在治疗肝脏糖代谢的药物的用途
HK40010029A (en) Combination of metabolic regulators and compounds for preventing and reducing the severity of chronic damage caused by diabetes
HK40010029B (en) Combination of metabolic regulators and compounds for preventing and reducing the severity of chronic damage caused by diabetes
OA19128A (en) Combination of metabolic regulators and nutraceuticals for the prevention of chronic damage from diabetes.
Vučević et al. Methionine-choline deprivation alters liver and brain acetylcholinesterase activity in C57BL6 mice
Ramon In vitro assessment of Kalanchoe pinnata and metformin preparation